Cybin Inc. (HELP)
| Market Cap | 257.93M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -123.22M |
| Shares Out | 50.04M |
| EPS (ttm) | -4.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,236,566 |
| Open | 5.38 |
| Previous Close | 5.40 |
| Day's Range | 5.15 - 5.50 |
| 52-Week Range | 4.29 - 9.83 |
| Beta | 1.04 |
| Analysts | Strong Buy |
| Price Target | 51.50 (+899.03%) |
| Earnings Date | Jul 1, 2026 |
About HELP
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for HELP stock is "Strong Buy." The 12-month stock price target is $51.5, which is an increase of 899.03% from the latest price.
News
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
NEW YORK & TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel seroton...
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
NEW YORK and TORONTO, April 23, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serot...
How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status,...
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serot...
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer
This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 20...
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic dr...
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
NEW YORK and TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel sero...
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
NEW YORK and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel sero...
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints
Helus Pharma (NASDAQ: HELP) shares are down on Thursday following the announcement of topline results from a Phase 2 signal detection study for HLP004, a potential treatment for generalized anxiety di...
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
Statistically significant (p
Cybin Transcript: Study result
Phase II results in GAD showed a rapid, clinically meaningful 10-point HAM-A reduction and sustained response and remission rates through six months, with a favorable safety profile. The deuterated DMT formulation enables rapid onset and discharge, supporting commercial potential.
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 202...
Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference: -7...
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
- Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events - - Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder (...
Cybin Initiates At-The-Market Equity Program of up to US$100 Million
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthca...
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative n...
Cybin Transcript: Jefferies London Healthcare Conference 2025
Late-stage clinical assets CYB003 and CYB004 target MDD and GAD with innovative, less frequent dosing regimens, aiming to improve access and reduce clinic burden. Phase 3 and Phase 2 data readouts are expected in the next year, supported by strong financial resources.
Cybin Earnings Call Transcript: Q2 2026
Leadership transition managed with operational stability, $175M financing closed, and debt retired. CYB003 phase III and CYB004 phase II trials progressing on schedule, with key data readouts expected in 2026. Cash runway extends into 2027, supporting late-stage development and commercial readiness.
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcar...
Cybin to Participate in the Jefferies Global Healthcare Conference in London
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental h...
Cybin Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Two late-stage clinical programs target depression and anxiety using novel psychedelics, with CYB003 in phase III for MDD and CYB004 in phase II for GAD. Robust efficacy, favorable safety, and strong financials support key data readouts next year.
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental h...
Cybin Transcript: Future of Health Summit 2025
Panelists highlighted the global burden and economic impact of mental health conditions, emphasizing the need for innovative treatments, digital tools, and environmental interventions. Policy, funding, and cultural shifts are essential to improve access, prevention, and equity in mental health care.
Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental h...
Cybin to Participate at the 2025 Milken Institute Future of Health Summit
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental h...